---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-26-000115"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2026-07-30T10:32:37+00:00"
generated_at: "2026-07-30T10:35:12.588068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 2026 mitapivat revenue $44.7M; net loss $100.7M; FDA Priority Review for sickle cell sNDA

## Summary
- Mitapivat worldwide net revenue $44.7M (Q2 2026) vs $12.5M (Q2 2025); U.S. $40.9M, ex-U.S. $3.8M.
- FDA granted Priority Review for mitapivat sNDA in sickle cell disease; PDUFA date Nov 1, 2026.
- Licensed cevidoplenib from Oscotec for ITP; up to $1B peak U.S. sales potential; $25M up-front payment.
- Discontinued tebapivat in LR-MDS and sickle cell disease; advancing AG-236 to Phase 2/3 for polycythemia vera.
- Cash, equivalents, and marketable securities $964.8M as of June 30, 2026; net loss $100.7M vs $112.0M.

## SEC filing metadata
- accession: 0001439222-26-000115
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2026-07-30T10:32:37+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/0001439222-26-000115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000115/agio-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-26-000115
- JSON: https://secwatch.observer/filing/0001439222-26-000115.json
- Plain text: https://secwatch.observer/filing/0001439222-26-000115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.